Amylyx Pharmaceuticals, Inc 10-Q for FY2026 Q3
Amylyx Pharmaceuticals, Inc. (AMLX)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
Amylyx Pharmaceuticals, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Amylyx Pharmaceuticals, Inc. reported that the Phase 3 LUCIDITY trial of avexitide reduced Level 2 and Level 3 hypoglycemic events 55% versus placebo. It plans to submit an FDA New Drug Application by the end of 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $45.49M
- compared with a net loss of $34.39M a year earlier
- Diluted EPS
- -$0.38
- compared with -$0.37 a year earlier